{"DataElement":{"publicId":"2749605","version":"1","preferredName":"Sjogren Syndrome Involvement Type","preferredDefinition":"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis._To have a connection by participation or association or use; sharing in an activity or process._Something distinguishable as an identifiable class based on common qualities.","longName":"SJO_SYN_INV_TYP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2749593","version":"1","preferredName":"Sjogren Syndrome Involvement","preferredDefinition":"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis._To have a connection by participation or association or use; sharing in an activity or process.","longName":"SJO_SYN_INV","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2674863","version":"1","preferredName":"Sjogren's Syndrome","preferredDefinition":"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.","longName":"C26883","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sjogren Syndrome","conceptCode":"C26883","definition":"An autoimmune disorder affecting the salivary and lacrimal glands. Morphologically, it is characterized by the presence of lymphocytic and plasmacytic infiltrates which cause destruction of these glands. It results in dry mouth and dry eyes. It may be associated with the presence of other autoimmune disorders, including rheumatoid arthritis and lupus erythematosus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"38ACD1C3-0DE1-0590-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-27","modifiedBy":"ONEDATA","dateModified":"2007-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2192548","version":"1","preferredName":"Involvement","preferredDefinition":"To have a connection by participation or association or use; sharing in an activity or process.","longName":"C25548","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9F4C3B9-9218-0989-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-11-29","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D2422EB-21A8-6421-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2749599","version":"1","preferredName":"Sjogren Syndrome Involvement Type","preferredDefinition":"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis._To have a connection by participation or association or use; sharing in an activity or process._Something distinguishable as an identifiable class based on common qualities.","longName":"SJO_SYN_INV_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"36","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"SICCA","valueDescription":"Sicca Syndrome","ValueMeaning":{"publicId":"2749600","version":"1","preferredName":"Sicca Syndrome","longName":"2749600","preferredDefinition":"A constellation of symptoms that include abnormal dryness of the mouth, eyes and other mucous membranes.  The condition is seen in patients with Sjogren syndrome, sarcoidosis, amyloidosis, and deficiencies of vitamins A and C.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sicca Syndrome","conceptCode":"C70647","definition":"A constellation of symptoms that include abnormal dryness of the mouth, eyes and other mucous membranes. The condition is seen in patients with Sjogren syndrome, sarcoidosis, amyloidosis, and deficiencies of vitamins A and C.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D244BB3-D430-6882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D244BB3-D449-6882-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"CZECHS","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Exocrine gland swelling","valueDescription":"Swelling Exocrine Gland","ValueMeaning":{"publicId":"2749601","version":"1","preferredName":"Swelling Exocrine Gland","longName":"2749601","preferredDefinition":"Enlargement; expansion in size; sign of inflammation: A gland from which secretions reach a free surface of the body by ducts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Swelling","conceptCode":"C3399","definition":"Enlargement; expansion in size; sign of inflammation","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Exocrine Gland","conceptCode":"C12712","definition":"A gland from which secretions reach a free surface of the body by ducts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D244BB3-D458-6882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D483A98-C56C-0C36-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Lymphoma, paraproteinemia","valueDescription":"Paraproteinemia Lymphoma","ValueMeaning":{"publicId":"2749603","version":"1","preferredName":"Paraproteinemia Lymphoma","longName":"2749603","preferredDefinition":"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Paraproteinemias may be seen in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases. --2004: A malignant (clonal) proliferation of B- or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites.  This category includes Non-Hodgkin's lymphomas and Hodgkin's lymphomas. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paraproteinemia","conceptCode":"C27468","definition":"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Paraproteinemias may be seen in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases. --2004","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D244BB3-D4A9-6882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D483A98-C581-0C36-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D483A98-C58D-0C36-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Other organ lymphocytic infiltration","valueDescription":"Lymphocytic Infiltration Other","ValueMeaning":{"publicId":"2749602","version":"1","preferredName":"Lymphocytic Infiltration Other","longName":"2749602","preferredDefinition":"Referring to lymphocytes, a type of white blood cell.: The diffusion or accumulation in a tissue or cells of substances not normal to it or in amounts above normal.: Not otherwise specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocytic","conceptCode":"C13350","definition":"Of or pertaining to lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Infiltration","conceptCode":"C25754","definition":"The process of the diffusion or accumulation in a tissue or cells of a substance not normal to it or in amounts above normal. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D244BB3-D481-6882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D483A98-C5A2-0C36-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Vasculitis","valueDescription":"Vasculitis","ValueMeaning":{"publicId":"2569497","version":"1","preferredName":"Vasculitis","longName":"2569497","preferredDefinition":"Inflammation of a blood vessel.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasculitis","conceptCode":"C26912","definition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-10","modifiedBy":"CZECHS","dateModified":"2008-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D483A98-C5AE-0C36-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2749598","version":"1","preferredName":"Sjogren's Syndrome Involvement Type","preferredDefinition":"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.:To have a connection by participation or association or use; sharing in an activity or process.:Type; a subdivision of a particular kind of thing.","longName":"C26883:C25548:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sjogren Syndrome","conceptCode":"C26883","definition":"An autoimmune disorder affecting the salivary and lacrimal glands. Morphologically, it is characterized by the presence of lymphocytic and plasmacytic infiltrates which cause destruction of these glands. It results in dry mouth and dry eyes. It may be associated with the presence of other autoimmune disorders, including rheumatoid arthritis and lupus erythematosus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D244BB3-D408-6882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"ONEDATA","dateModified":"2008-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D244BB3-D419-6882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedDiagnosis:resultClassificationCode ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"For the sjogren syndrome, wha","type":"Preferred Question Text","description":"For the sjogren syndrome, what was the involved organ or clinical problem?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2749605","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.resultClassificationCode WHERE PerformedDiagnosis.value = \"sjogren syndrome\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D244BB3-D4FC-6882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-13","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}